Biogen takes Creative Biolabs to court over antibody

Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Danish university sues Creative Biolabs over ‘antibody pirating’

9 December 2020 The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.

Biotechnology

Roche stakes $2bn on UCB Alzheimer’s disease treatment

30 July 2020 Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.

Americas

Five core IP legal principles in life sciences

9 July 2020 In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Biogen takes Creative Biolabs to court over antibody

More on this story

Editor's picks

Editor's picks

More features